Micro Medical Solutions

Greg Sullivan, Founder and CEO, leads the MMS management team. Mr. Sullivan has extensive experience in the Medical Device Industry with over 25 years in the minimally invasive neurology and cardiology market. His extensive experience combines a traditional corporate background with leadership roles in several emerging technology medical device companies. He has been involved in the successful launch of over 25 products in the endovascular, interventional cardiology, interventional neurology and ENT markets. His leadership has taken these devices from development to building innovative minimally invasive technology through demonstrated clinical outcomes, to acquisition and sale of a mature organization.

Mr. Sullivan has held Senior Management positions for both public and venture backed private companies.   He has served in progressively responsible roles for Arterial Vascular Engineering (acquired by Medtronic, 1998, $4.3 billion), Precision Vascular Solutions (acquired by Boston Scientific, 2002, $80 million), Acclarent, Inc. (acquired by J&J 2007, $785 million), Chestnut Medical (acquired by EV3/Covidien 2008 $100 million). Several of the products in which he was intimately involved with remain industry leaders to this day.

Jihad Mustapha, MD, Chief Medical Officer is an interventional cardiologist who specializes in endovascular revascularization of PVD: specifically, CLI. He is the co-founder and CEO of Advanced Cardiac and Vascular Amputation Prevention Centers in Grand Rapids, Michigan. He also serves as Clinical Associate Professor of Medicine at Michigan State University College of Osteopathic Medicine. Dr. Mustapha speaks internationally on the topic of CLI, alternative access, atherectomy, vessel morphology, calcification and drug eluting technology.

Dr. Mustapha graduated from Wayne State University and St. George University School of Medicine and has completed Fellowships in both Cardiology and Interventional Cardiology at Louisiana State University School of Medicine. He is a Fellow of the American College of Cardiology and Fellow of the Society of Cardiac Angiography and Intervention and has multiple publications on CLI and limb salvage. He is the Founder and Director of the AMPutation Prevention Symposium and is a Founding Board Member of the CLI Global Society.

Greg Mathison, Vice President of Regulatory Affairs, has more than 35 years of experience in the healthcare industry and has supported the regulatory pathway for 510k approval for more than 200 product submissions to the FDA. He also has been instrumental in the submission of IDE and PMA applications to the FDA, as well as technical dossiers to foreign governments for CE Mark approval.

Beginning his career in the medical device industry as a chemical engineer at Medtronic in 1979, Mr. Mathison moved to regulatory affairs in 1984. He has held management positions in regulatory affairs at Medtronic, Cardiac Pacemakers, Clarus Medical Systems and Bacchus Vascular. In 1993, he founded Regulatory Strategies, a full-service consulting firm focusing on U.S. and international regulatory affairs, clinical strategies and quality systems. He continues to specialize in strategic regulatory planning and in finding creative solutions to regulatory issues.

Regulatory Affairs Certified (RAC), Mr. Mathison has served as Co-chair of the Medical Alley Regulatory Committee. He is a frequent presenter on regulatory affairs, clinical studies and quality compliance at professional conferences and medical device industry professional groups and organizations.

Mr. Mathison has a bachelor of arts degree in chemistry from St. Olaf College in Northfield, Minn.

Dawn Davila, VP of Engineering and Operations joined MMS at it’s inception as a Program Manager. Her background in neuro and peripheral vascular disease treatment along with her leadership in developing and promoting a culture of innovation with the philosophy of being thought leaders in the treatment of BTK disease, earned her the position of VP of Engineering and Operations.

Dawn has close to 20 years of experience with cross functional responsibilities including engineering, research and development, manufacturing, program management, and business development. She has defined product development milestones and successfully driven cross functional teams towards those milestones. Her leadership role in pre-commercial development activities includes: Implants, Delivery Systems, Guide and Balloon Guide catheters for cardiovascular, neurovascular, and peripheral vascular disease.

She holds a BS in Mechanical Engineering from Northeastern University.

Lynn Bougie, Vice President of Quality and Management Representative has over 15 years of multi-functional medical device experience across a range of start-ups and larger corporations. Her roles in quality assurance, regulatory affairs and project management have defined and promoted a quality atmosphere across MMS. As VP of Quality and Management Representative, Lynn has developed and scaled the quality management system to support each phase of growth for MMS. Her guidance provides the MMS team confidence in delivering high quality products in compliance with regulatory requirements.

Lynn’s leadership roles across multi-functional teams working to design, develop, and manufacture new and innovative medical technologies has led her to bring high-quality products to market from early concept to first human use and commercial release. Lynn’s experience spans across cardiovascular, neurovascular, gynecology, gastroenterology, colorectal, spinal, endoscopy, and airway devices. She has been responsible for implementing, obtaining certifications, and maintaining quality management systems and associated device design and manufacturing records in compliance with ISO 13485, FDA 21 CFR Part 820, EU MDD, EU MDR and other regulations. She has participated in preparation of regulatory submissions for clinical studies, FDA 510(k) and De Novo, and EU technical documentation for CE Mark. She is responsible for successfully representing and leading the MMS team through notified body audits and FDA inspections.
Prior to joining MMS, Lynn served as the Director of Quality at several medical device companies including Iogyn, acquired by Boston Scientific, and Pelvalon, Inc., acquired by Laborie.

Lynn has a BS in Mechanical Engineering from Northeastern University.

Rita Jacob, a proven Clinical Affairs strategist, joined MMS in 2022. She brings a history of collaborating with medical device company executives and key stakeholders to deliver results in FDA regulated clinical research, medical training and scientific marketing. After spending nearly a decade in cardiovascular intensive care nursing, Rita evolved her passion for exceptional patient care to delivering novel high-risk medical devices into physicians’ hands for over 25 years. Her career has included Fortune 100 and 500 companies as well as many start-up companies. Team focus, results orientation and ethical behavior is her ethos.

Rita has many career firsts that include the first FDA approved aortic stent graft, first interventional venous thrombus protection device, first US industry data registries with the Society of Vascular Surgery and the American Venous Forum and the first to obtain FDA approval to change a PMA clinical study strategy from RCT to TPG. For these Class III device projects Rita developed study protocols that met FDA PMA requirements, recruited qualified study investigators/sites, managed the studies in compliance with Good Clinical Practices (GCP) and prepared final statistical analyses and PMA study reports. She has established and completed publication strategies resulting in physician authored manuscript acceptance in Tier I and II peer reviewed journals. Rita creates and delivers training curricula to physicians and company sales, marketing, engineering and customer service employees.

Rita has a BS in Nursing from the University of Maryland. RN licensure incudes Maryland and California, now inactive.